The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT03471065
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT03471065
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03471065. Allocation not applicable; no masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2019-12-23 (actual). Results posted on 2021-01-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis
- Condition
- Aortic Valve Stenosis
- Intervention (Device)
- SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV
- Lead sponsor
- Edwards Lifesciences
Record details
- Record id
cardio:ct-nct03471065- Content hash
7a98837d5417455a6d834ef9b31dd93a90fb94e13250d22020253c9ca2debb7d